EMF biological effects
Share

Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20 degrees C and thawing by microwave radiation.

L Keusters, L M Stolk, R Umans, P Van Asten

PAPERpubmedPharmaceutisch weekblad. Scientific edition1986OtherEffect: no_effectEvidence: Insufficient

Abstract

Doxorubicin and epirubicin solutions in plastic minibags for intravesical use were stored at -20 degrees C and thawed at room temperature or by microwave radiation. Concentrations were measured with HPLC and TLC. Doxorubicin and epirubicin solutions could be frozen and stored at -20 degrees C during at least two and four weeks, respectively, and subsequently thawed without loss of content. When the thawed doxorubicin solutions were refrozen and thawed again five weeks later, only a slight decrease of content was measured.

AI evidence extraction

At a glance
Study type
Other
Effect direction
no_effect
Population
—
Sample size
—
Exposure
microwave
Evidence strength
Insufficient
Confidence: 74% · Peer-reviewed: yes

Main findings

Doxorubicin and epirubicin solutions stored at -20°C and thawed either at room temperature or by microwave radiation showed no loss of content after at least 2 weeks (doxorubicin) and 4 weeks (epirubicin). Refreezing and re-thawing doxorubicin five weeks later resulted in only a slight decrease in content.

Outcomes measured

  • Drug concentration/content stability after freezing and thawing (doxorubicin
  • epirubicin)

Limitations

  • No sample size reported in abstract
  • Microwave exposure parameters (e.g.
  • frequency
  • power
  • duration) not reported
  • Study focuses on pharmaceutical stability rather than biological/health outcomes
View raw extracted JSON
{
  "study_type": "other",
  "exposure": {
    "band": null,
    "source": "microwave radiation (thawing)",
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": null
  },
  "population": null,
  "sample_size": null,
  "outcomes": [
    "Drug concentration/content stability after freezing and thawing (doxorubicin, epirubicin)"
  ],
  "main_findings": "Doxorubicin and epirubicin solutions stored at -20°C and thawed either at room temperature or by microwave radiation showed no loss of content after at least 2 weeks (doxorubicin) and 4 weeks (epirubicin). Refreezing and re-thawing doxorubicin five weeks later resulted in only a slight decrease in content.",
  "effect_direction": "no_effect",
  "limitations": [
    "No sample size reported in abstract",
    "Microwave exposure parameters (e.g., frequency, power, duration) not reported",
    "Study focuses on pharmaceutical stability rather than biological/health outcomes"
  ],
  "evidence_strength": "insufficient",
  "confidence": 0.74,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "doxorubicin",
    "epirubicin",
    "intravesical",
    "plastic minibags",
    "-20°C storage",
    "freezing",
    "thawing",
    "microwave radiation",
    "HPLC",
    "TLC",
    "stability"
  ],
  "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.

NNEMF synthesis

Synthesis pending.

Original record: rfsafe.org paper 6198

Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20 degrees C and thawing by microwave radiation. · Non-native EMF